FEG
GSK icon

Financial Enhancement Group’s GSK GSK Stock Holding History

Financial Enhancement Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-320
Closed -$17K – 303
2019
Q1 		$17K Buy
+320
New +$16K 0.01% 189

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Financial Enhancement Group's GSK Position: Q2 2019 in Review

Financial Enhancement Group sold out of GSK (GSK) in Q2 2019, closing a stake of 320 shares — an estimated $17K sold.

Financial Enhancement Group first reported a position in GSK in Q1 2019 and held it in 1 quarter. The position peaked at $17K in Q1 2019. 804 funds tracked by Wall St. Rank hold GSK as of Q2 2019.

  • Financial Enhancement Group reported no remaining GSK position as of Q2 2019 after selling out during the quarter.
  • Financial Enhancement Group sold 320 GSK shares in Q2 2019, an estimated $17K.
  • Financial Enhancement Group first reported a position in GSK in Q1 2019 and held it in 1 quarter.
  • Financial Enhancement Group's GSK position peaked at $17K in Q1 2019.
  • 804 funds tracked by Wall St. Rank held GSK as of Q2 2019.

Based on Financial Enhancement Group's 13F filing for Q2 2019, filed 6 Aug 2019.